p53 inhibits the upregulation of sirtuin 1 expression induced by c‑Myc

Yuan,Fang; Liu,Lu; Lei,Yonghong; Tang,Peifu

doi:10.3892/ol.2017.6661

p53 inhibits the upregulation of sirtuin 1 expression induced by c‑Myc

Authors:
- Fang Yuan
- Lu Liu
- Yonghong Lei
- Peifu Tang
View Affiliations

Affiliations: Department of Oncology, General Hospital of Chinese PLA, Beijing 100853, P.R. China, Department of Clinical Nutrition, General Hospital of Chinese PLA, Beijing 100853, P.R. China, Key Laboratory of Wound Repair and Regeneration of The First Affiliated Hospital of Chinese PLA General Hospital, Beijing 100048, P.R. China, Department of Orthopedics, General Hospital of Chinese PLA, Beijing 100853, P.R. China
Published online on: July 24, 2017 https://doi.org/10.3892/ol.2017.6661
Pages: 4396-4402

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Sirtuin 1 (Sirt1), a conserved NAD+ dependent deacetylase, is a mediator of life span by calorie restriction. However, Sirt1 may paradoxically increase the risk of cancer. Accordingly, the expression level of Sirt1 is selectively elevated in numerous types of cancer cell; however, the mechanisms underlying the differential regulation remain largely unknown. The present study demonstrated that oncoprotein c‑Myc was a direct regulator of Sirt1, which accounts for the upregulation of Sirt1 expression only in the cells without functional p53. In p53 deficient cells, the overexpression of c‑Myc increased Sirt1 mRNA and protein expression levels as well as its promoter activity, whereas the inhibitor of c‑Myc, 10058‑F4, induced decreased Sirt1 basal mRNA and protein expression levels. Deletion/mutation mapping analyses revealed that c‑Myc bound to the conserved E‑box[‑189 to ‑183 base pair (bp)] of the Sirt1 promoter. In addition, p53 and c‑Myc shared at least response element and the presence of p53 may block the binding of c‑Myc to the Sirt1 promoter, thus inhibit the c‑Myc mediated upregulation of Sirt1 promoter activity. The present study indicated that the expression level of Sirt1 was tightly regulated by oncoprotein c‑Myc and tumor suppressor p53, which aids an improved understanding of its expression regulation and tumor promoter role in certain conditions.

View Figures

View References

1	Liu TF and McCall CE: Deacetylation by SIRT1 reprograms inflammation and cancer. Genes Cancer. 4:135–147. 2013. View Article : Google Scholar : PubMed/NCBI
2	Wang C, Chen L, Hou X, Li Z, Kabra N, Ma Y, Nemoto S, Finkel T, Gu W, Cress WD and Chen J: Interactions between E2F1 and SirT1 regulate apoptotic response to DNA damage. Nat Cell Biol. 8:1025–1031. 2006. View Article : Google Scholar : PubMed/NCBI
3	McCall CE, El Gazzar M, Liu T, Vachharajani V and Yoza B: Epigenetics, bioenergetics, andmicroRNA coordinate gene-specific reprogramming during acute systemic inflammation. J Leukoc Biol. 90:439–446. 2011. View Article : Google Scholar : PubMed/NCBI
4	Hida Y, Kubo Y, Murao K and Arase S: Strong expression of a longevity-related protein, SIRT1, in Bowen's disease. Arch Dermatol Res. 299:103–106. 2007. View Article : Google Scholar : PubMed/NCBI
5	Huffman DM, Grizzle WE, Bamman MM, Kim JS, Eltoum IA, Elgavish A and Nagy TR: SIRT1 is significantly elevated in mouse and human prostate cancer. Cancer Res. 67:6612–6618. 2007. View Article : Google Scholar : PubMed/NCBI
6	Hennig D, Müller S, Wichmann C, Drube S, Pietschmann K, Pelzl L, Grez M, Bug G, Heinzel T and Krämer OH: Antagonism between granulocytic maturation and deacetylase inhibitor-induced apoptosis in acute promyelocytic leukaemia cells. Br J Cancer. 112:329–337. 2015. View Article : Google Scholar : PubMed/NCBI
7	Jang KY, Hwang SH, Kwon KS, Kim KR, Choi HN, Lee NR, Kwak JY, Park BH, Park HS, Chung MJ, et al: SIRT1 expression is associated with poor prognosis of diffuse large B-cell lymphoma. Am J Surg Pathol. 32:1523–1531. 2008. View Article : Google Scholar : PubMed/NCBI
8	Shah ZH, Ahmed SU, Ford JR, Allison SJ, Knight JR and Milner J: A deacetylase-deficient SIRT1 variant opposes full-length SIRT1 in regulating tumor suppressor p53 and governs expression of cancer-related genes. Mol Cell Biol. 32:704–716. 2012. View Article : Google Scholar : PubMed/NCBI
9	Vahtola E, Louhelainen M, Forstén H, Merasto S, Raivio J, Kaheinen P, Kytö V, Tikkanen I, Levijoki J and Mervaala E: Sirtuin1-p53, forkhead box O3a, p38 and post-infarct cardiac remodeling in the spontaneously diabetic Goto-Kakizaki rat. Cardiovasc Diabetol. 9:52010. View Article : Google Scholar : PubMed/NCBI
10	Nemoto S, Fergusson MM and Finkel T: Nutrient availability regulates SIRT1 through a forkhead-dependent pathway. Science. 306:2105–2108. 2004. View Article : Google Scholar : PubMed/NCBI
11	Chen WY, Wang DH, Yen RC, Luo J, Gu W and Baylin SB: Tumor suppressor HIC1 directly regulates SIRT1 to modulate p53-dependent DNA-damage responses. Cell. 123:437–448. 2005. View Article : Google Scholar : PubMed/NCBI
12	Mao B, Zhao G, Lv X, Chen HZ, Xue Z, Yang B, Liu DP and Liang CC: Sirt1 deacetylates c-Myc and promotes c-Myc/Max association. Int J Biochem Cell Biol. 43:1573–1581. 2011. View Article : Google Scholar : PubMed/NCBI
13	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
14	Yamaguchi H, Woods NT, Piluso LG, Lee HH, Chen J, Bhalla KN, Monteiro A, Liu X, Hung MC and Wang HG: P53 acetylation is crucial for its transcription-independent proapoptotic functions. J Biol Chem. 284:11171–11183. 2009. View Article : Google Scholar : PubMed/NCBI
15	Rothmann T, Hengstermann A, Whitaker NJ, Scheffner M and zur Hausen H: Replication of ONYX-015, a potential anticancer adenovirus, is independent of p53 status in tumor cells. J Virol. 72:9470–9478. 1998.PubMed/NCBI
16	D'Orazi G, Cecchinelli B, Bruno T, Manni I, Higashimoto Y, Saito S, Gostissa M, Coen S, Marchetti A, Del Sal G, et al: Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser 46 and mediates apoptosis. Nat Cell Biol. 4:11–19. 2002. View Article : Google Scholar : PubMed/NCBI
17	Wang S, Song P and Zou MH: Inhibition of AMP-activated protein kinase α (AMPKα) by doxorubicin accentuates genotoxic stress and cell death in mouse embryonic fibroblasts and cardiomyocytes: Role of p53 and SIRT1. J Biol Chem. 287:8001–8012. 2012. View Article : Google Scholar : PubMed/NCBI
18	Xie Y, Bulbul MA, Ji L, Inouye CM, Groshen SG, Tulpule A, O'Malley DP, Wang E and Siddiqi IN: P53 expression is a strong marker of inferior survival in de novo diffuse large B-cell lymphoma and may have enhanced negative effect with MYC coexpression: A single institutional clinicopathologic study. Am J Clin Pathol. 141:593–604. 2014. View Article : Google Scholar : PubMed/NCBI
19	Ho JS, Ma W, Mao DY and Benchimol S: P53-dependent transcriptional repression of c-myc is required for G1 cell cycle arrest. Mol Cell Biol. 25:7423–7431. 2005. View Article : Google Scholar : PubMed/NCBI
20	Ta VB, de Bruijn MJ, ter Brugge PJ, van Hamburg JP, Diepstraten HJ, van Loo PF, Kersseboom R and Hendriks RW: Malignant transformation of Slp65-deficient pre-B cells involves disruption of the Arf-Mdm2-p53 tumor suppressor pathway. Blood. 115:1385–1393. 2010. View Article : Google Scholar : PubMed/NCBI
21	Sachdeva M, Zhu S, Wu F, Wu H, Walia V, Kumar S, Elble R, Watabe K and Mo YY: P53 represses c-Myc through induction of the tumor suppressor miR-145. Proc Natl Acad Sci USA. 106:3207–3212. 2009. View Article : Google Scholar : PubMed/NCBI
22	Molinuevo R, Freije A, de Pedro I, Stoll SW, Elder JT and Gandarillas A: FOXM1 allows human keratinocytes to bypass the oncogene-induced differentiation checkpoint in response to gain of MYC or loss of p53. Oncogene. 36:956–965. 2017. View Article : Google Scholar : PubMed/NCBI
23	Tanaka H, Tamura A, Sekai M, Hamazaki Y and Minato N: Increased c-Myc activity and DNA damage in hematopoietic progenitors precede myeloproliferative disease in Spa-1-deficiency. Cancer Sci. 102:784–791. 2011. View Article : Google Scholar : PubMed/NCBI
24	Li L, Osdal T, Ho Y, Chun S, McDonald T, Agarwal P, Lin A, Chu S, Qi J, Li L, et al: SIRT1 activation by a c-MYC oncogenic network promotes the maintenance and drug resistance of human FLT3-ITD acute myeloid leukemia stem cells. Cell Stem Cell. 15:431–446. 2014. View Article : Google Scholar : PubMed/NCBI
25	Savage KJ, Johnson NA, Ben-Neriah S, Connors JM, Sehn LH, Farinha P, Horsman DE and Gascoyne RD: MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. Blood. 114:3533–3537. 2009. View Article : Google Scholar : PubMed/NCBI
26	Liu Y, Gong LP, Dong XL and Liu HG: Detection of C-MYC oncogene translocation and copy number change in the normal-dysplasia-carcinoma sequence of the larynx by fluorescence in situ hybridization. Diagn Cytopathol. 41:515–519. 2013. View Article : Google Scholar : PubMed/NCBI
27	Balz V, Scheckenbach K, Götte K, Bockmühl U, Petersen I and Bier H: Is the p53 inactivation frequency in squamous cell carcinomas of the head and neck underestimated? Analysis of p53 exons 2–11 and human papillomavirus 16/18 E6 transcripts in 123 unselected tumor specimens. Cancer Res. 63:1188–1191. 2003.PubMed/NCBI